Board of Directors

John D. Finney is Chairman of the Board of Directors. Along with his brother, Michael J. Finney, Ph.D., Mr. Finney founded and grew MJ Research and MJ Bioworks, two businesses were the premier providers of instrumentation and reagents for genome analysis. Mr. Finney received his A.B. in Economics from Harvard University. He continues to serve as Chairman of Gcorp, Inc. and of GeneWorks Pty Ltd.

Dr. Finney is an investor based in San Francisco. He was a founder of MJ Research, and is currently an investor in over a dozen privately-held companies in biotechnology, alternative energy, and allied areas. Dr. Finney received his Ph.D. in Biology from the Massachusetts Institute of Technology with Dr. H. Robert Horvitz, and was a Postdoctoral Fellow at Massachusetts General Hospital with Dr. Gary Ruvkun. He holds six U.S. patents.

Mr. Lakey is President and Chief Executive Officer and a member of the Board of Directors. Mr. Lakey joined Orion when it was founded as Vice President of Technology Operations and has served as President and Chief Executive Officer since June 2000. Mr. Lakey has 17 years of experience in genomics. Prior to coming to Orion Genomics, he was Director of DNA Sequencing at Millennium Pharmaceuticals, Inc., in Cambridge, Massachusetts (1994-98). There, he established and managed Millennium's large-scale sequencing department, and participated in strategic planning and business development efforts. Mr. Lakey's implementation of DNA sequencing quickly became fundamental to Millennium's technology platform. Before joining Millennium, Mr. Lakey worked as a Research Associate with Dr. George Church at Harvard Medical School's Department of Genetics where he focused on technology development for the Human Genome Project. Mr. Lakey received his B.A. in Biochemistry from the University of Texas (Austin).

Dr. Martienssen is a member of the Board of Directors and a scientific co-founder of the Company. He is a Professor in plant genetics at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, and leads the plant biology group there. As well as developing strategies to exploit methylation in genome sequencing, Dr. Martienssen has also investigated the link between DNA methylation, histone methylation, and RNA interference in plants and yeast. His work, along with that of his colleagues, was awarded the "Breakthrough of the Year" by the journal, Science, in 2002. Dr. Martienssen was a co-recipient of the Kumho International Science Award in 2001 and was the 2003 recipient of the Newcomb Cleveland Award. Dr. Martienssen received his B.A. in Natural Sciences (Genetics) from Cambridge University, England and his Ph.D. from the Plant Breeding Institute and Cambridge University. He held an EMBO postdoctoral fellowship at the University of California at Berkeley and has been on the faculty at Cold Spring Harbor Laboratory since 1989. Dr. Martienssen was elected Fellow of the Royal Society on May 18, 2006.

Dr. McCombie is a member of the Board of Directors and a scientific co-founder of the Company. He is a Professor at Cold Spring Harbor Laboratory, Cold Spring Harbor, New York. Dr. McCombie received his B.A. in Biology from Wabash College, his Ph.D. in Cell and Molecular Biology from the University of Michigan, and was a Postdoctoral Fellow in the Microbiology Department of the University of Texas (Austin). He worked in the area of yeast gene expression at Phillips Petroleum, and was a Senior Staff Fellow at the National Institutes of Health, where he was the leader of one of the first groups to carry out large-scale automated sequencing of genomic DNA and helped to organize the first large-scale EST sequencing project. He has been on the faculty at Cold Spring Harbor Laboratory since 1992.

Dr. McPherson is Acting Vice President of Research and Development, a member of the Board of Directors, and is a scientific co-founder of the Company. He is currently the Cancer Genomics Director and Senior Principal Investigator at the Ontario Institute for Cancer Research, Toronto, Canada. He is focusing on genomic and proteomic characterization of cancer stem cells for biomarker discovery for improved imaging and diagnostic and treatment potential. Previously, he was Associate Professor of Molecular and Human Genetics at Baylor College of Medicine and faculty member of the Human Genome Sequencing Center (2003-2007) where his research focused on utilizing high-throughput genomic resources to study human disease and functional genomics. Dr. McPherson's prior appointments were Associate Professor of Genetics and Co-Director of the Genome Sequencing Center at Washington University School of Medicine, St. Louis, Missouri (1995-2003) and Assistant Professor of Biological Chemistry and Co-Director of the Human Genome Research Center at the University of California at Irvine (1994-1995). Dr. McPherson is an expert in physical mapping and positional cloning and played a lead role in the generation of the human and mouse physical maps as part of the Human Genome Project. Dr. McPherson received his B.S. and Ph.D. in Biochemistry from Queen's University (Ontario) and was a Postdoctoral Fellow in the Biochemistry Department at the University of California (Irvine).

Dr. Wilson is a member of the Board of Directors and a scientific co-founder of the Company. He served as Interim CEO and Chairman of the Board of Directors during Orion's start-up phase. Dr. Wilson is Professor of Genetics and Molecular Microbiology and is Director of the Genome Sequencing Center (GSC) at Washington University School of Medicine, St. Louis, Missouri, one of the foremost genome centers in the world. Dr. Wilson received his B.A. in Microbiology from Miami University (Ohio), his Ph.D. in Chemistry from the University of Oklahoma, and held a postdoctoral Research Fellowship in the Division of Biology at the California Institute of Technology.